Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00743314 · ClinicalTrials.gov registry record · Early Phase 1

Single-Photon Emission Computed Tomography, Computed Tomography Lymphoscintigraphy, and Intensity-Modulated Radiation Therapy in Treating Patients Who Have Undergone Surgery for Stage I or Stage II Breast Cancer

A Early Phase 1 study, sponsored by Mayo Clinic.

Completed
Registry status
Early Phase 1
Development phase
30
Enrollment target

NCT00743314: Completed Early Phase 1 study, sponsored by Mayo Clinic.

NCT00743314 is a Early Phase 1 study that has completed, run by Mayo Clinic. The registered enrollment target is 30 participants. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00743314, a Early Phase 1 study, has completed, sponsored by Mayo Clinic.

COMPLETED
Registry status
Early Phase 1
Development phase
30 participants
Enrollment target

Study Summary

RATIONALE: Diagnostic procedures, such as single-photon emission computed tomography and computed tomography lymphoscintigraphy, may help lower the dose of radiation therapy after surgery, and help prevent lymphedema. PURPOSE: This clinical trial is studying single-photon emission computed tomography and computed tomography lymphoscintigraphy followed by intensity-modulated radiation therapy to see how well they work in treating patients who have undergone surgery for stage I or stage II breast cancer.

Interventions

  • RADIATION intensity-modulated radiation therapy
  • OTHER screening questionnaire administration
  • PROCEDURE computed tomography
  • PROCEDURE single photon emission computed tomography
  • PROCEDURE lymphoscintigraphy

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2008-09
Est. Completion 2016-10
Phase Early Phase 1

Sponsor

Mayo Clinic

2,844 total trials

What the Registry Record Tells You About NCT00743314

The ClinicalTrials.gov registry entry for NCT00743314 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 5 interventions - of which intensity-modulated radiation therapy is the first listed.

NCT00743314 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00743314 about?

NCT00743314 is a clinical study titled "Single-Photon Emission Computed Tomography, Computed Tomography Lymphoscintigraphy, and Intensity-Modulated Radiation Therapy in Treating Patients Who Have Undergone Surgery for Stage I or Stage II Breast Cancer". RATIONALE: Diagnostic procedures, such as single-photon emission computed tomography and computed tomography lymphoscintigraphy, may help lower the dose of radiation therapy after surgery, and help prevent lymphedema. PURPOSE: This clinical trial is studying single-photon emission computed tomograp...

What is the current status of trial NCT00743314?

This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 30 participants. The study started on 2008-09. Estimated completion is 2016-10.

What interventions are being tested in trial NCT00743314?

The interventions under investigation include: intensity-modulated radiation therapy (RADIATION), screening questionnaire administration (OTHER), computed tomography (PROCEDURE), single photon emission computed tomography (PROCEDURE), lymphoscintigraphy (PROCEDURE).

Who is sponsoring clinical trial NCT00743314?

This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.